Pancreatic Neoplasms Clinical Trial
Official title:
An Open Label, Stratified, Single-arm Phase II Study of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy
Verified date | May 2013 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study was to assess the efficacy and safety of everolimus in the treatment of advanced pancreatic neuroendocrine tumor (NET) not responsive to cytotoxic chemotherapy. All patients were treated with everolimus until either tumor progression was documented using a standard criteria that measures tumor size called Response Evaluation Criteria in Solid tumors (RECIST), or until unacceptable toxicity occurred, or until the patient or investigator requested discontinuation of treatment.
Status | Completed |
Enrollment | 160 |
Est. completion date | April 2012 |
Est. primary completion date | January 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria for both strata: - Advanced (unresectable or metastatic) biopsy-proven pancreatic Neuroendocrine tumor (NET) - Confirmed low-grade or intermediate-grade neuroendocrine carcinoma - Objective disease progression by Response Evaluation Criteria in Solid tumors (RECIST) criteria while receiving cytotoxic chemotherapy or at any time after receiving an adequate course of cytotoxic chemotherapy (i.e., at least 3 consecutive cycles or months of treatment with the same cytotoxic drug or regimen) - Presence of at least one measurable disease using RECIST criteria at screening (computer tomography [CT] or Magnetic resonance imaging [MRI]) - Adequate bone marrow, liver and kidney function - WHO Performance Status 0-2. Inclusion criteria for Stratum 2 only: - Meet all inclusion criteria defined above for both strata. - Receiving treatment (at least 3 consecutive months) with Octreotide Depot. - In addition to documentation of progressive disease on or after chemotherapy, patients in stratum 2 must have documented objective progression of disease while receiving Octreotide Depot. Exclusion criteria for both strata: - Anticancer therapy within 3 weeks of enrollment. - Patients with poorly differentiated neuroendocrine carcinoma - Hepatic artery embolization within the last 6 months - Prior therapy with everolimus or other rapamycins (sirolimus, temsirolimus) - Other concurrent malignancy - Other serious intercurrent infections or nonmalignant uncontrolled medical illnesses Exclusion Criterion for Stratum 1 only: • Received treatment with Octreotide Depot or any other long-acting somatostatin analogue in the 60 days prior to enrollment or any short-acting somatostatin analogue in the two weeks prior to enrollment. Other protocol-defined inclusion/exclusion criteria applied. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Argentina | Novartis Investigative Site | Buenos Aires | |
Argentina | Novartis Investigative Site | Santa Fe | |
Australia | Novartis Investigative Site | Heidelberg | |
Australia | Novartis Investigative Site | Herston | |
Australia | Novartis Investigative Site | Kogarah | |
Belgium | Novartis Investigative Site | Leuven | |
Canada | Novartis Investigative Site | Halifax | Nova Scotia |
Canada | Novartis Investigative Site | London | Ontario |
Canada | Novartis Investigative Site | Montreal | Quebec |
Canada | Novartis Investigative Site | Toronto | Ontario |
Canada | Novartis Investigative Site | Vancouver | British Columbia |
France | Novartis Investigative Site | Billancourt | |
France | Novartis Investigative Site | Clichy Cedex | |
France | Novartis Investigative Site | Lyon Cedex | |
France | Novartis Investigative Site | Reims | |
France | Novartis Investigative Site | Toulouse | |
France | Novartis Investigative Site | Villejuif Cedex | |
Germany | Novartis Investigative Site | Berlin | |
Germany | Novartis Investigative Site | Erlangen | |
Germany | Novartis Investigative Site | Essen | |
Germany | Novartis Investigative Site | Frankfurt | |
Germany | Novartis Investigative Site | Heidelberg | |
Germany | Novartis Investigative Site | Marburg | |
Germany | Novartis Investigative Site | Ulm | |
Italy | Novartis Investigative Site | Milano | |
Italy | Novartis Investigative Site | Modena | |
Italy | Novartis Investigative Site | Pisa | |
Italy | Novartis Investigative Site | Rome | |
Italy | Novartis Investigative Site | Torrette di Ancona | |
Netherlands | Novartis Investigative Site | Gronigen | |
Spain | Novartis Investigative Site | Barcelona | |
Spain | Novartis Investigative Site | L'Hospitalet de Llobregat | |
Spain | Novartis Investigative Site | Madrid | |
Sweden | Novartis Investigative Site | Uppsala | |
United States | Emory University Hospital | Atlanta | Georgia |
United States | The University of Alabama at Birmingham | Birmingham | Alabama |
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | Arthur G. James Cancer Hospital/Ohio State University | Columbus | Ohio |
United States | Duke University Medical Center | Durham | North Carolina |
United States | M. D Anderson Cancer Center | Houston | Texas |
United States | University of Iowa Hospitals and Clinics | Iowa City | Iowa |
United States | Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire |
United States | Cedars-Sinai Outpatient Cancer Center/Samuel Oschin Comprehensive Cancer Inst. | Los Angeles | California |
United States | UCLA Medical Center | Los Angeles | California |
United States | USC Medical Center | Los Angeles | California |
United States | University of Wisconsin Hospital & Clinics | Madison | Wisconsin |
United States | University of Miami | Miami | Florida |
United States | LSUHC Multispecialty Clinic | New Orleans | Louisiana |
United States | Lynn Ratner, M.D. | New York | New York |
United States | Oregon Health and Science University | Portland | Oregon |
United States | Mayo Clinic | Rochester | Minnesota |
United States | UCSF Comprehensive Cancer Center | San Francisco | California |
United States | H. Lee Moffit Cancer Center & Research Institute | Tampa | Florida |
United States | Scott & White Memorial Hospital | Temple | Texas |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
United States, Argentina, Australia, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate: Percentage of Participants With Best Over All Response of Complete Response or Partial Response by Central Radiology Review (Stratum 1) Based on Response Evaluation Criteria in Solid Tumors (RECIST) | Objective response rate was defined by RECIST criteria: Partial response (PR) must have = 30% decrease in the sum of longest diameter of all target lesions, from the baseline sum. Complete response (CR) must have disappearance of all target and non-target lesions. For CR or PR, tumor measurements must be confirmed by 2nd assessments within 4 weeks. Progression = 20% increase in the sum of longest diameter of all target lesions, from smallest sum of longest diameter of all target lesions recorded at or after baseline; or a new lesion; or progression of non-target lesions. | from date of randomization/start of treatment until first documented response confirmed 4 weeks later( at least 3 months) | No |
Secondary | Duration of Overall Response (Stratum 1) Based on Response Evaluation Criteria in Solid Tumors (RECIST)- Central Radiology Review | Duration of overall response applies only to patients whose best overall response was complete response (CR) or partial response (PR): Complete Response (CR) = at least two determinations of CR at least 4 weeks apart before progression. Partial response (PR) = at least two determinations of PR or better at least 4 weeks apart before progression. Progression = 20% increase in the sum of the longest diameter of all target lesions, from the smallest sum of longest diameter of all target lesions recorded at or after baseline; or a new lesion; or progression of non-target lesions |
from date of first documented confirmed response to time to progression, at least 3 months | No |
Secondary | Duration of Overall Response (Stratum 2) Based on Response Evaluation Criteria in Solid Tumors (RECIST)- Central Radiology Review | Duration of overall response applies only to patients whose best overall response was complete response (CR) or partial response (PR): Complete Response (CR) = at least two determinations of CR at least 4 weeks apart before progression. Partial response (PR) = at least two determinations of PR or better at least 4 weeks apart before progression. Progression = 20% increase in the sum of the longest diameter of all target lesions, from the smallest sum of longest diameter of all target lesions recorded at or after baseline; or a new lesion; or progression of non-target lesions |
from date of first documented confirmed response to time to progression, at least 3 months | No |
Secondary | Objective Response Rate: Percentage of Participants With Best Over All Response of Complete Response or Partial Response by Central Radiology Review (Stratum 2) Based on Response Evaluation Criteria in Solid Tumors (RECIST) | Objective response rate was defined by RECIST criteria: Partial response (PR) must have = 30% decrease in the sum of longest diameter of all target lesions, from the baseline sum. Complete response (CR) must have disappearance of all target and non-target lesions. For CR or PR, tumor measurements must be confirmed by 2nd assessments within 4 weeks. Progression = 20% increase in the sum of longest diameter of all target lesions, from smallest sum of longest diameter of all target lesions recorded at or after baseline; or a new lesion; or progression of non-target lesions. | from date of randomization/start of treatment until first documented response confirmed 4 weeks later (at least 3 months) | No |
Secondary | Number of Participants With Adverse Events (AEs), Death, Serious Adverse Events (SAEs)[Stratum 1] | Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards. | on or after the day of the first intake of study treatment to starting no later than 28 days after study treatment discontinuation, at least every month | Yes |
Secondary | Number of Participants With Adverse Events (AEs), Death, Serious Adverse Events (SAEs) [Stratum 2] | Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards. | on or after the day of the first intake of study treatment to starting no later than 28 days after study treatment discontinuation, at least every month | Yes |
Secondary | Time to Progression Free Survival (PFS) Per Central Radiology Review (Stratum 1) | Progression free survival (PFS) is defined as the time from randomization to the date of first documented disease progression or death from any cause. The Kaplan-Meier estimate of the PFS survival function was constructed. Median PFS was obtained and displayed along with 95% confidence intervals. |
from randomisation to dates of disease progression, death from any cause or last tumor assessment, reported between day of first patient randomised, 26 June 2006, until cut-off date 13 September 2010 | No |
Secondary | Time to Progression Free Survival (PFS) Per Central Radiology Review (Stratum 2) | Progression free survival (PFS) is defined as the time from randomization to the date of first documented disease progression or death from any cause. The Kaplan-Meier estimate of the PFS survival function was constructed. Median PFS was obtained and displayed along with 95% confidence intervals. |
from randomisation to dates of disease progression, death from any cause or last tumor assessment, reported between day of first patient randomised, 26 June 2006, until cut-off date 13 September 2010 | No |
Secondary | Time to Overall Survival (OS)(Stratum 1) | Overall survival measures the time of survival , with any response or disease progression, until death. The OS is defined as the time from date of start of treatment to date of death due to any cause. If a patient is not known to have died, survival was censored at the date of last contact. In each treatment stratum, the Kaplan-Meier estimate of the overall survival function was constructed. |
from randomisation to dates of disease progression, death from any cause, reported between day of first patient randomised, 26 June 2006, until cut-off date 13 April 2012 | No |
Secondary | Time to Overall Survival (OS) (Stratum 2) | Overall survival measures the time of survival , with any response or disease progression, until death. The OS is defined as the time from date of start of treatment to date of death due to any cause. If a patient is not known to have died, survival was censored at the date of last contact. In each treatment stratum, the Kaplan-Meier estimate of the overall survival function was constructed. |
from randomisation to dates of disease progression, death from any cause, reported between day of first patient randomised, 26 June 2006, until cut-off date 13 April 2012 | No |
Secondary | Everolimus Trough Level Determination by Pharmacokinetics Parameter in Both Strata (Stratum 1 and 2) | For all patients in both strata, a blood sample for everolimus trough level determination will be collected immediately prior to the everolimus administration on Cycle 1 Day 15, Cycle 2 Day 1, and every month thereafter. A treatment cycle was defined as 28 days of consecutive daily treatment with everolimus and treatment continued until tumor progression. It is critical that patients not take their daily everolimus dose before the sample is drawn. | Cycle 1 Day 15 | No |
Secondary | Effect of Octreotide Depot on the Trough Concentrations of Everolimus | The effect of Octreotide Depot on the trough concentrations of everolimus was assessed at Cycle 1 Day 15. | Cycle 1 Day 1, Cycle 2 Day 1 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04085055 -
Fine Needle Biopsy of Solid Pancreatic Mass Lesions
|
N/A | |
Recruiting |
NCT01950572 -
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
|
||
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Recruiting |
NCT04809935 -
EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy
|
Phase 4 | |
Recruiting |
NCT05481476 -
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04652271 -
International Pancreatic Surgery Outcomes Study - PancreasGroup.Org
|
||
Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
Completed |
NCT02909530 -
Comparison Between Olympus EZ Shot 3Plus 19G and EZ Shot 2 19G in EUS-guided FNB of Solid Pancreatic Masses
|
N/A | |
Completed |
NCT03054987 -
Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction
|
N/A | |
Completed |
NCT02374411 -
Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients
|
N/A | |
Completed |
NCT01770405 -
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
|
N/A | |
Terminated |
NCT01313416 -
Gemcitabine and CT-011 for Resected Pancreatic Cancer
|
Phase 2 | |
Terminated |
NCT01515046 -
Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer
|
Phase 2 | |
Enrolling by invitation |
NCT01465425 -
Extracolonic Findings on Computed Tomography (CT) Colonography
|
||
Terminated |
NCT01434459 -
Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
|
Phase 1 | |
Completed |
NCT00985777 -
Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia
|
Phase 1 | |
Completed |
NCT00385177 -
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00178763 -
Hyperthermia With Chemotherapy for Locally Advanced or Metastatic Pancreas Cancer
|
Phase 2 | |
Completed |
NCT00196105 -
Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)
|
N/A |